No needles: Xoma Labs wins $200k for a non-invasive glucose monitor ring

What just happened

Diabetes Australia has announced the results of its 2026 Grand Innovation Challenge: a ring-based wearable device that reads glucose levels continuously, without needles, without a sensor inserted under the skin, and without finger pricks.

Xoma Labs won $200,000 from the $500,000 prize pool, competing against six finalists in a challenge that specifically sought solutions grounded in the lived experience of people managing diabetes. An apex clinical trial is scheduled to begin in January 2027.

The prize is real. The funding is secured. The technology is early stage. The promise, if it holds up in trials, is substantial. What follows is an honest account of what each of those things actually means.

Both-and

The promise

Non-invasive continuous glucose monitoring has been a research aspiration for decades. The appeal is obvious: for someone managing type 1 diabetes, or type 2 diabetes on insulin, the current reality of sensor-based continuous glucose monitoring means a small sensor inserted into subcutaneous tissue, replaced every ten to fourteen days, that reads glucose from interstitial fluid continuously.

Current TGA-approved glucose monitors have been genuinely transformative for people living with diabetes — particularly in reducing hypoglycaemia risk and providing trend data that point-in-time readings cannot give. But insertion means a consumable component, a replacement schedule, occasional site discomfort, and for some people with needle phobia or skin sensitivity, a real barrier to uptake.

A wearable ring that achieves continuous monitoring without insertion would address those barriers for a meaningful number of people. The question that matters clinically is whether non-invasive measurement can achieve the accuracy needed for clinical decision-making, particularly around insulin dosing and hypoglycaemia detection.

The history of caution

Non-invasive glucose sensing has a long and largely unsuccessful commercial history. Watches, patches, optical devices, and spectroscopy-based systems have been trialled over the past two decades. The consistent pattern has been promising bench performance that does not hold up across the full range of real-world variables: different skin tones, ambient temperatures, hydration states, physical activity levels, and — critically — the hypoglycaemic range where clinical decisions are most consequential.

Achieving accuracy comparable to inserted sensors without a calibration reference that is itself in contact with interstitial fluid or blood has proven extremely difficult. The devices that have reached market as consumer wellness devices (not medical devices) have done so with accuracy thresholds that fall well short of what clinical use requires.

Xoma Labs’ apex trial starting in January 2027 will be the first meaningful test of whether this specific device performs as described under real clinical conditions. An innovation prize validates a promising approach and funds the next step — it is not accuracy data.

What this means for people with diabetes right now

What it means: Australian researchers are investing in non-invasive glucose monitoring technology, and this approach has cleared a rigorous innovation assessment by Diabetes Australia. That is a credible signal of scientific promise.

What it doesn’t mean: people currently managing diabetes who are frustrated with sensor-based CGM cannot access this device. The timeline from a successful clinical trial to a commercially available, TGA-approved product involves multiple regulatory steps that typically take several years in the best case.

For anyone who has seen social media content about “needle-free diabetes technology” in recent months, this announcement is the important context: the technology is not available, the trial has not yet started, and the accuracy claims have not yet been tested in a clinical setting.

The current generation of TGA-approved glucose monitors — subsidised under the National Diabetes Services Scheme (NDSS) — remains the best available technology for continuous glucose monitoring in Australia today.

Why innovation challenges matter

Diabetes Australia’s Grand Innovation Challenge is a legitimate mechanism for surfacing and funding technologies that might otherwise struggle to move from proof of concept to clinical trial. A $200,000 prize, and $500,000 distributed across six finalists, can make the difference between an idea that stays in a university lab and one that enters a clinical trial.

Dr Erin Saricilar, Xoma’s Chief Medical Officer, is quoted noting the funding will support the apex trial directly. For a small company working in a space where clinical trials are expensive and the regulatory pathway is long, this funding matters.

Whether the trial results will justify the next stage of development depends entirely on the accuracy data.

My two cents

The historical pattern with non-invasive glucose sensing is that devices perform reasonably at normal and elevated glucose ranges but lose accuracy in the hypoglycaemic range — the range that matters most clinically for people dosing insulin. If Xoma’s January 2027 trial results show robust accuracy across the full spectrum, this becomes a genuinely significant development. If the hypoglycaemic accuracy is insufficient, it joins a long list of promising non-invasive approaches that did not reach clinical utility.

This is worth following. It is not worth presenting to patients as a near-term clinical option.

Verdict: maybe — promising approach, funding secured, trial starting in 2027. Worth watching; not yet applicable to clinical care decisions.

---

Sources cited

1. Wearable non-invasive continuous glucose monitor leads innovation challenge. Diabetes Australia, 19 August 2026. https://www.diabetesaustralia.com.au/mediarelease/wearable-non-invasive-continuous-glucose-monitor-leads-innovation-challenge/